- Home
- PLYA vs BEAM Comparison
PLYA vs BEAM Comparison
Compare PLYA & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLYA
- BEAM
- Stock Information
- Founded
- PLYA 2006
- BEAM 2017
- Country
- PLYA Netherlands
- BEAM United States
- Employees
- PLYA N/A
- BEAM N/A
- Industry
- PLYA Hotels/Resorts
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLYA Consumer Discretionary
- BEAM Health Care
- Exchange
- PLYA Nasdaq
- BEAM Nasdaq
- Market Cap
- PLYA 1.7B
- BEAM 1.6B
- IPO Year
- PLYA N/A
- BEAM 2020
- Fundamental
- Price
- PLYA $13.48
- BEAM $16.76
- Analyst Decision
- PLYA Hold
- BEAM Strong Buy
- Analyst Count
- PLYA 5
- BEAM 11
- Target Price
- PLYA $12.00
- BEAM $48.90
- AVG Volume (30 Days)
- PLYA 1.5M
- BEAM 1.8M
- Earning Date
- PLYA 08-04-2025
- BEAM 08-05-2025
- Dividend Yield
- PLYA N/A
- BEAM N/A
- EPS Growth
- PLYA 8.44
- BEAM N/A
- EPS
- PLYA 0.49
- BEAM N/A
- Revenue
- PLYA $896,462,000.00
- BEAM $63,578,000.00
- Revenue This Year
- PLYA N/A
- BEAM N/A
- Revenue Next Year
- PLYA $7.12
- BEAM $8.82
- P/E Ratio
- PLYA $27.72
- BEAM N/A
- Revenue Growth
- PLYA N/A
- BEAM N/A
- 52 Week Low
- PLYA $6.95
- BEAM $13.53
- 52 Week High
- PLYA $13.51
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- PLYA 61.81
- BEAM 44.29
- Support Level
- PLYA $13.43
- BEAM $16.18
- Resistance Level
- PLYA $13.51
- BEAM $18.33
- Average True Range (ATR)
- PLYA 0.01
- BEAM 1.10
- MACD
- PLYA -0.00
- BEAM 0.00
- Stochastic Oscillator
- PLYA 50.00
- BEAM 28.65
About PLYA Playa Hotels & Resorts N.V.
Playa Hotels & Resorts NV acts as an owner, operator, and developer of all-inclusive resorts in prime beachfront locations in popular vacation destinations in Mexico and the Caribbean. The company has four reportable segments by geography, including the Yucatan Peninsula, Pacific Coast, Dominican Republic, and Jamaica. It generates a majority of its revenue from the Yucatan Peninsula segment. Its brand profile consists of Hyatt Ziva, Hyatt Zilara, Hilton, Jewel Resorts, and others.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.